{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:41:34Z","timestamp":1789062094841,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Ardea Biosciences, Inc., San Diego, CA, a wholly owned subsidiary of AstraZeneca PLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-1107-x","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T07:25:51Z","timestamp":1475479551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney"],"prefix":"10.1186","volume":"18","author":[{"given":"Jeffrey N.","family":"Miner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip K.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hyndman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Iverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Nanavati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Hagerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Manhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zancong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Girardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tain","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Terkeltaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Quart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,3]]},"reference":[{"issue":"5","key":"1107_CR1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","volume":"364","author":"T Neogi","year":"2011","unstructured":"Neogi T. Clinical practice: gout. N Engl J Med. 2011;364(5):443\u201352.","journal-title":"N Engl J Med"},{"issue":"4","key":"1107_CR2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1107_CR3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","volume":"58","author":"RC Lawrence","year":"2008","unstructured":"Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum. 2008;58(1):26\u201335.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1107_CR4","first-page":"1582","volume":"31","author":"KL Wallace","year":"2004","unstructured":"Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10\u00a0years among older adults in a managed care population. J Rheumatol. 2004;31(8):1582\u20137.","journal-title":"J Rheumatol"},{"issue":"10","key":"1107_CR5","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136\u201341.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1107_CR6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649\u201362.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"1107_CR7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40273-015-0288-5","volume":"33","author":"GE Shields","year":"2015","unstructured":"Shields GE, Beard SM. A systematic review of the economic and humanistic burden of gout. Pharmacoeconomics. 2015;33(10):1029\u201347.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"1107_CR8","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G, British Society for Rheumatology, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46(8):1372\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1107_CR9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, et al. 2012 American College of Rheumatology guidelines for management of gout, part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447\u201361.","journal-title":"Arthritis Care Res"},{"key":"1107_CR10","first-page":"448","volume":"71 suppl 3","author":"P Khanna","year":"2012","unstructured":"Khanna P, Hagerty D, Mischler R, Morlock R. Adherence to EULAR recommendations for the treatment of gout [EULAR abstract FRI0397]. Ann Rheum Dis. 2012;71 suppl 3:448.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1107_CR11","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, et al. EULAR evidence based recommendations for gout, part II: management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1107_CR12","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, et al. EULAR evidence based recommendations for gout, part I: diagnosis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1301\u201311.","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"1107_CR13","doi-asserted-by":"publisher","first-page":"30071","DOI":"10.1016\/j.jbspin.2016.04.007","volume":"S1297\u2013319X","author":"S Liu","year":"2016","unstructured":"Liu S, Perez-Ruiz F, Miner JN. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. Joint Bone Spine. 2016;S1297\u2013319X(16):30071\u20139. doi: 10.1016\/j.jbspin.2016.04.007 .","journal-title":"Joint Bone Spine"},{"issue":"1","key":"1107_CR14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","volume":"6","author":"R Terkeltaub","year":"2010","unstructured":"Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010;6(1):30\u20138.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"1107_CR15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","volume":"143","author":"HK Choi","year":"2005","unstructured":"Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499\u2013516.","journal-title":"Ann Intern Med"},{"issue":"9654","key":"1107_CR16","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(08)61343-4","volume":"372","author":"A Dehghan","year":"2008","unstructured":"Dehghan A, K\u00f6ttgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, Boerwinkle E, Levy D, Hofman A, Astor BC, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372(9654):1953\u201361.","journal-title":"Lancet"},{"issue":"6","key":"1107_CR17","doi-asserted-by":"crossref","first-page":"e1000504","DOI":"10.1371\/journal.pgen.1000504","volume":"5","author":"M Kolz","year":"2009","unstructured":"Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5(6):e1000504.","journal-title":"PLoS Genet"},{"issue":"2","key":"1107_CR18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ng.2500","volume":"45","author":"A Kottgen","year":"2013","unstructured":"Kottgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, Pistis G, Ruggiero D, O'Seaghdha CM, Haller T, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45(2):145\u201354.","journal-title":"Nat Genet"},{"issue":"6887","key":"1107_CR19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447\u201352.","journal-title":"Nature"},{"issue":"1","key":"1107_CR20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.ASN.0000105320.04395.D0","volume":"15","author":"K Ichida","year":"2004","unstructured":"Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, Hosoya T. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol. 2004;15(1):164\u201373.","journal-title":"J Am Soc Nephrol"},{"issue":"40","key":"1107_CR21","doi-asserted-by":"crossref","first-page":"26834","DOI":"10.1074\/jbc.C800156200","volume":"283","author":"N Anzai","year":"2008","unstructured":"Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem. 2008;283(40):26834\u20138.","journal-title":"J Biol Chem"},{"issue":"6","key":"1107_CR22","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ajhg.2008.11.001","volume":"83","author":"H Matsuo","year":"2008","unstructured":"Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K, Wiriyasermkul P, Kikuchi Y, Oda T, Nishiyama J, et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet. 2008;83(6):744\u201351.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"1107_CR23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ng.106","volume":"40","author":"V Vitart","year":"2008","unstructured":"Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008;40(4):437\u201342.","journal-title":"Nat Genet"},{"issue":"6","key":"1107_CR24","doi-asserted-by":"crossref","first-page":"R220","DOI":"10.1186\/ar4417","volume":"15","author":"TJ Flynn","year":"2013","unstructured":"Flynn TJ, Phipps-Green A, Hollis-Moffatt JE, Merriman ME, Topless R, Montgomery G, Chapman B, Stamp LK, Dalbeth N, Merriman TR. Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects. Arthritis Res Ther. 2013;15(6):R220.","journal-title":"Arthritis Res Ther"},{"issue":"5\u20136","key":"1107_CR25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/B:CARD.0000015855.02485.e3","volume":"17","author":"AJ Reyes","year":"2003","unstructured":"Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003;17(5\u20136):397\u2013414.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"1107_CR26","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1681\/ASN.2007010106","volume":"18","author":"Y Hagos","year":"2007","unstructured":"Hagos Y, Bahn A, Vormfelde SV, Brockmoller J, Burckhardt G. Torasemide transport by organic anion transporters contributes to hyperuricemia. J Am Soc Nephrol. 2007;18(12):3101\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1107_CR27","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1681\/ASN.2006040415","volume":"18","author":"Y Hagos","year":"2007","unstructured":"Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol. 2007;18(2):430\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1107_CR28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/annrheumdis-2011-201186","volume":"72","author":"MA McAdams-DeMarco","year":"2013","unstructured":"McAdams-DeMarco MA, Maynard JW, Baer AN, Kao LW, Kottgen A, Coresh J. A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study. Ann Rheum Dis. 2013;72(5):701\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1107_CR29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003088-198106020-00004","volume":"6","author":"RF Cunningham","year":"1981","unstructured":"Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet. 1981;6(2):135\u201351.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1107_CR30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","volume":"136","author":"G Burckhardt","year":"2012","unstructured":"Burckhardt G. Drug transport by organic anion transporters (OATs). Pharmacol Ther. 2012;136(1):106\u201330.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"1107_CR31","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","volume":"31","author":"M-HH Lee","year":"2008","unstructured":"Lee M-HH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout: was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643\u201365.","journal-title":"Drug Saf"},{"key":"1107_CR32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.phrs.2015.09.012","volume":"102","author":"G Derosa","year":"2015","unstructured":"Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63\u201370.","journal-title":"Pharmacol Res"},{"issue":"6","key":"1107_CR33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/2040622315596119","volume":"6","author":"ML Wolff","year":"2015","unstructured":"Wolff ML, Cruz JL, Vanderman AJ, Brown JN. The effect of angiotensin II receptor blockers on hyperuricemia. Ther Adv Chronic Dis. 2015;6(6):339\u201346.","journal-title":"Ther Adv Chronic Dis"},{"issue":"12","key":"1107_CR34","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/rheumatology\/ket487","volume":"53","author":"R Fleischmann","year":"2014","unstructured":"Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner JN, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford). 2014;53(12):2167\u201374.","journal-title":"Rheumatology (Oxford)"},{"key":"1107_CR35","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.2147\/DDDT.S85193","volume":"9","author":"Z Shen","year":"2015","unstructured":"Shen Z, Rowlings C, Kerr B, Hingorani V, Manhard K, Quart B, Yeh LT, Storgard C. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. Drug Des Dev Ther. 2015;9:3423\u201334.","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"1107_CR36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MNH.0b013e32835ddad2","volume":"22","author":"DB Mount","year":"2013","unstructured":"Mount DB. The kidney in hyperuricemia and gout. Curr Opin Nephrol Hypertens. 2013;22(2):216\u201323.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"1107_CR37","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","volume":"75","author":"F Perez-Ruiz","year":"2016","unstructured":"Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C, Group RS. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016;75(6):1074\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1107_CR38","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40265-016-0550-y","volume":"76","author":"SM Hoy","year":"2016","unstructured":"Hoy SM. Lesinurad. First Global Approval. Drugs. 2016;76(4):509\u201316.","journal-title":"Drugs"},{"issue":"2","key":"1107_CR39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/clpt.2008.195","volume":"85","author":"KS Fenner","year":"2009","unstructured":"Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, Lee CA. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009;85(2):173\u201381.","journal-title":"Clin Pharmacol Ther"},{"issue":"18","key":"1107_CR40","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1111\/j.1742-4658.2011.08171.x","volume":"278","author":"OM Woodward","year":"2011","unstructured":"Woodward OM, Kottgen A, Kottgen M. ABCG transporters and disease. FEBS J. 2011;278(18):3215\u201325.","journal-title":"FEBS J"},{"issue":"6","key":"1107_CR41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40261-016-0386-y","volume":"36","author":"Z Shen","year":"2016","unstructured":"Shen Z, Yeh LT, Wallach K, Zhu N, Kerr B, Gillen M. In vitro and in vivo interaction studies between lesinurad, a selective urate reabsorption inhibitor, and major liver or kidney transporters. Clin Drug Investig. 2016;36(6):443\u201352.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"1107_CR42","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/hep.20634","volume":"41","author":"P Kaufmann","year":"2005","unstructured":"Kaufmann P, Torok M, Hanni A, Roberts P, Gasser R, Krahenbuhl S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology. 2005;41(4):925\u201335.","journal-title":"Hepatology"},{"issue":"2","key":"1107_CR43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF00562509","volume":"4","author":"J Broekhuysen","year":"1972","unstructured":"Broekhuysen J, Pacco M, Sion R, Demeulenaere L, Van Hee M. Metabolism of benzbromarone in man. Eur J Clin Pharmacol. 1972;4(2):125\u201330.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"1107_CR44","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00002018-200730090-00002","volume":"30","author":"J Karalliedde","year":"2007","unstructured":"Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf. 2007;30(9):741\u201353.","journal-title":"Drug Saf"},{"key":"1107_CR45","doi-asserted-by":"crossref","first-page":"36092","DOI":"10.1155\/2007\/36092","volume":"2007","author":"C Kunishima","year":"2007","unstructured":"Kunishima C, Inoue I, Oikawa T, Nakajima H, Komoda T, Katayama S. Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors. PPAR Res. 2007;2007:36092.","journal-title":"PPAR Res"},{"key":"1107_CR46","doi-asserted-by":"crossref","unstructured":"Bardin T, Keenan R, Khanna P, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, So A. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: results from a phase III study in gout patients having an inadequate response to standard of care (CLEAR 2). Poster presented at 16th EULAR Annual European Congress of Rheumatology, Rome, Italy, June 10-13, 2015; Poster FRI0333.","DOI":"10.1136\/annrheumdis-2015-eular.1238"},{"key":"1107_CR47","doi-asserted-by":"crossref","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker M. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: results from a phase III study in gout patients having an inadequate response to standard of care (CLEAR 1). Poster presented at 16th EULAR Annual European Congress of Rheumatology, Rome, Italy, June 10-13, 2015; Poster FRI0320.","DOI":"10.1136\/annrheumdis-2015-eular.3273"},{"key":"1107_CR48","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00003495-197714050-00002","volume":"14","author":"RC Heel","year":"1977","unstructured":"Heel RC, Brogden RN, Speight TM, Avery GS. Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. Drugs. 1977;14:349\u201366.","journal-title":"Drugs"},{"issue":"12","key":"1107_CR49","first-page":"1791","volume":"33","author":"T Iwanaga","year":"2005","unstructured":"Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos. 2005;33(12):1791\u20135.","journal-title":"Drug Metab Dispos"},{"key":"1107_CR50","unstructured":"U.S. Department of Health and Human Services. Guidance for Industry. Drug Interaction Studies-\u2014Study Design, Data Analysis, Implications for Dosing and Labeling Recommendations. US Food and Drug Administration. February 2012. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm292362.pdf ."},{"issue":"4","key":"1107_CR51","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpt1977224395","volume":"22","author":"J Honari","year":"1977","unstructured":"Honari J, Blair AD, Cutler RE. Effects of probenecid on furosemide kinetics and natriuresis in man. Clin Pharmacol Ther. 1977;22(4):395\u2013401.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1107_CR52","doi-asserted-by":"crossref","first-page":"F867","DOI":"10.1152\/ajprenal.00528.2007","volume":"294","author":"V Vallon","year":"2008","unstructured":"Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK. Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008;294(4):F867\u201373.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"1107_CR53","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/17425255.2012.667401","volume":"8","author":"EI Lepist","year":"2012","unstructured":"Lepist EI, Ray AS. Renal drug-drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol. 2012;8(4):433\u201348.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"1107_CR54","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.2215\/CJN.02440314","volume":"10","author":"SK Nigam","year":"2015","unstructured":"Nigam SK, Wu W, Bush KT, Hoenig MP, Blantz RC, Bhatnagar V. Handling of Drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters. Clin J Am Soc Nephrol. 2015;10(11):2039\u201349.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"1107_CR55","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1371\/journal.pmed.0050197","volume":"5","author":"MJ Caulfield","year":"2008","unstructured":"Caulfield MJ, Munroe PB, O'Neill D, Witkowska K, Charchar FJ, Doblado M, Evans S, Eyheramendy S, Onipinla A, Howard P, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5(10):e197.","journal-title":"PLoS Med"}],"updated-by":[{"DOI":"10.1186\/s13075-016-1150-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T00:00:00Z","timestamp":1476230400000}}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-1107-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T02:21:06Z","timestamp":1568427666000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-1107-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,3]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1107"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-1107-x","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13075-016-1150-7","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,3]]},"article-number":"214"}}